Skip to Content

Etravirine Dosage

Medically reviewed on April 20, 2017.

Applies to the following strengths: 100 mg; 200 mg; 25 mg

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for HIV Infection

200 mg orally twice a day after a meal

Use: In combination with other antiretroviral agents, for the treatment of HIV-1 infection in antiretroviral therapy-experienced patients with evidence of viral replication and HIV-1 strains resistant to an NNRTI and other antiretroviral agents

Usual Pediatric Dose for HIV Infection

6 to less than 18 years:
-Weight 16 to less than 20 kg: 100 mg orally twice a day after a meal
-Weight 20 to less than 25 kg: 125 mg orally twice a day after a meal
-Weight 25 to less than 30 kg: 150 mg orally twice a day after a meal
-Weight at least 30 kg: 200 mg orally twice a day after a meal

Comments:
-Special attention should be given to accurate dose selection, transcription of the medication order, dispensing information, and dosing instructions to reduce the risk of medication errors, overdosing, and underdosing.

Use: In combination with other antiretroviral agents, for the treatment of HIV-1 infection in antiretroviral therapy-experienced patients with evidence of viral replication and HIV-1 strains resistant to an NNRTI and other antiretroviral agents

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Mild or moderate liver dysfunction (Child-Pugh A or B): No adjustment recommended.
Severe liver dysfunction (Child-Pugh C): Data not available

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 6 years; this drug is not recommended for use in these patients.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Comments:
-This drug is highly protein-bound; significant removal by dialysis is unlikely.

Other Comments

Administration advice:
-Always use in combination with other antiretroviral agents.
-Administer after a meal; the type of food does not affect drug exposure.
-Swallow tablet(s) whole with a liquid (such as water).
-For patients unable to swallow tablet(s) whole: May disperse tablet(s) in a glass of water; drink dispersion immediately, rinse the glass (with water, orange juice, or milk) several times, and completely swallow each rinse to ensure the entire dose is consumed.

Storage requirements:
-Store at 25C (77F) in original bottle; excursions permitted to 15C to 30C (59F to 86F).
-Keep bottle tightly closed to protect from moisture; do not remove desiccant pouches.

Reconstitution/preparation techniques:
-To prepare dispersion:
---Place the tablet(s) in 5 mL of water, or at least enough liquid to cover the medication.
---Stir well until the water looks milky.
---If desired, add more water or alternatively orange juice or milk; the tablet(s) should not be placed in orange juice or milk without first adding water. Avoid using grapefruit juice, warm beverages (above 40C [104F]), or carbonated beverages.

General:
-Indication is based on week 48 analyses from 2 clinical trials in clinically advanced, 3-class antiretroviral therapy-experienced adults and on 24-week analysis of a trial in antiretroviral therapy-experienced patients 6 to less than 18 years of age.
-The following should be considered when starting this drug in therapy-experienced patients:
---Treatment history and resistance testing should guide use of this drug (due to potential cross-resistance).
---This drug should not be used in combination with only N[t]RTIs in patients with virologic failure on an NNRTI-containing regimen.
---Use of other active antiretroviral agents with this drug associated with increased likelihood of treatment response.
---Safety and efficacy have not been established in therapy-naive patients.

Patient advice:
-Read the US FDA-approved patient labeling (Patient Information).
-Contact healthcare provider at once if rash develops; stop this drug and seek medical attention if rash associated with fever, general malaise, fatigue, muscle/joint aches, blisters, oral lesions, conjunctivitis, facial swelling, swelling of the eyes/lips/mouth, breathing difficulty, and/or signs/symptoms of liver problems (e.g., yellowing of skin/whites of eyes, dark/tea-colored urine, pale-colored stools/bowel movements, nausea, vomiting, loss of appetite, pain/aching/sensitivity on right side below ribs) develops.
-Notify healthcare provider at once of any symptoms of infection.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide